Previous 10 | Next 10 |
Growth driven by efficient Avenova ® direct-to-consumer e-marketing programs NovaBay ® Pharmaceuticals, Inc . (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase ...
2024-03-26 17:03:28 ET More on NovaBay Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay Read the full article on Seeking Alpha For further details see: NovaBay GAAP EPS of -$1.33...
Q4 net sales from the eyecare and wound care segment grew 10% over the prior year with higher sales from the Avenova ® physician dispensed and OTC channels, and from branded wound care products Sales and marketing expenses for the quarter declined 27% reflecting digital marketing...
NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and 12 months ended December 31, 2023 after market close on Tuesday, March 26, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. E...
DERMAdoctor sale reduces operating expenses and bolsters cash NovaBay ® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces that the Company has entered into an agreement to sell its DERMAd...
EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S. Und...
MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the latest results of the fall 2023 drilling campaign, on the Crevier niobium & tantalum project (the “Crevier Proje...
MONTREAL, Feb. 21, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce that, in accordance with the requirements of the TSX Venture Exchange and further to its news release dated February 7, 2024 (e...
MONTREAL, Feb. 07, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is pleased to announce the execution of a definitive option agreement (the “Option Agreement”, the “Option”), with Vior In...
2024-01-30 09:26:33 ET More on NovaBay NovaBay Pharmaceuticals, Inc. (NBY) Q3 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on NovaBay Historical earnings data for NovaBay Financial information for NovaBay Read the full article o...
News, Short Squeeze, Breakout and More Instantly...
NovaBay Pharmaceuticals Inc. Company Name:
NBY Stock Symbol:
NYSE Market:
NovaBay Pharmaceuticals Inc. Website:
Partnership co-promoting NovaBay’s Avenova ® Antimicrobial Lid & Lash Solution to large ophthalmic surgery centers along with one of Eyenovia’s FDA-approved product MydCombi™ Preparing for Eyenovia's launch of clobetasol propionate ophthalmic suspension, ...
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces it will be offering special promotions and discounts on its Avenova ® -branded eyecare products to customers and eyecare professionals throughout July in support of National Dry Eye Awareness Month. National Dry Eye Awarene...
MONTRÉAL, June 27, 2024 (GLOBE NEWSWIRE) -- NioBay Metals Inc. (“NioBay” or the “Company”) (TSX-V: NBY) (OTCQB: NBYCF) is proud to announce that, following the start of exploration work on the Foothills project, assay results confirm the presence of high TiO 2 ...